Key result
Low-dose DOAC thromboprophylaxis for 6 months was cost-effective for preventing VTE in intermediate-to-high risk cancer patients, with an ICER of $11,947 per QALY gained.
Why the study?
Randomized controlled trials have demonstrated that low-dose DOACs may reduce cancer-associated VTE, but their cost-effectiveness was not established.
Is low-dose DOAC thromboprophylaxis cost-effective compared to placebo for the prevention of VTE in patients with cancer at intermediate-to-high risk?
Is low-dose DOAC thromboprophylaxis cost-effective compared to placebo for the prevention of VTE in patients with cancer at intermediate-to-high risk?
Low-dose DOAC thromboprophylaxis for 6 months is a highly cost-effective strategy for preventing VTE in cancer patients at intermediate-to-high risk, particularly those with a Khorana score ≥3.
Answers are grounded in this paper and cite their sources.
May support low-dose DOAC use in intermediate-high risk cancer; leaves open need for randomized confirmation.
BACKGROUND: Randomized controlled trials (RCTs) have demonstrated that low-dose direct oral anticoagulants (DOACs), including rivaroxaban and apixaban, may help reduce the incidence of cancer-associated venous thromboembolism (VTE). METHODS: A cost-utility analysis was performed from the health sector perspective using a Markov state-transition model in patients with cancer who are at intermediate-to-high risk for VTE. Transition probability, relative risk, cost, and utility inputs were obtained from a meta-analysis of the RCTs and relevant epidemiology studies. Differences in cost, quality-adjusted life-years (QALYs), and the incremental cost-effectiveness ratio (ICER) per patient were calculated over a lifetime horizon. One-way, probabilistic, and scenario sensitivity analyses were conducted. RESULTS: In patients with cancer at intermediate-to-high risk for VTE, treatment with low-dose DOAC thromboprophylaxis for 6 months, compared with placebo, was associated with 32 per 1000 fewer VTE and 11 per 1000 more major bleeding episodes over a lifetime. The incremental cost and QALY increases were $1445 and 0.12, respectively, with an ICER of $11,947 per QALY gained. Key drivers of ICER variations included the relative risks of VTE and bleeding as well as drug cost. This strategy was 94% cost effective at the threshold of $50,000 per QALY. The selection of patients with Khorana scores ≥3 yielded the greatest value, with an ICER of $5794 per QALY gained. CONCLUSIONS: Low-dose DOAC thromboprophylaxis for 6 months appears to be cost-effective in patients with cancer who are at intermediate-to-high risk for VTE. The implementation of this strategy in patients with Khorana scores ≥3 may lead to the highest cost-benefit ratio.
No takes yet. Share an insight, caveat, or question.
Li et al. (2020) studied Cancer at intermediate-to-high risk for VTE. Low-dose direct oral anticoagulant (DOAC) vs. placebo was evaluated on Incremental cost-effectiveness ratio (ICER) per QALY gained (ICER $11,947). Low-dose DOAC thromboprophylaxis for 6 months was cost-effective for preventing VTE in intermediate-to-high risk cancer patients, with an ICER of $11,947 per QALY gained.
Synapse has enriched 10 related papers. Consider them for comparative context: